SEC Comment Letter for Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Mar 9, 2020
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: March 9, 2020 · CIK: 0001711786 · Accession: 0000000000-20-002104
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236887
Letter
March 9, 2020 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed March 4, 2020 File No. 333-236887 Dear Mr. Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia J. Khan, Esq.
Show Raw Text
March 9, 2020
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, New York 10020
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 4, 2020
File No. 333-236887
Dear Mr. Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nazia J. Khan, Esq.